Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocet plus cyclophosphamide and trastuzumab versus doxorubicin plus cyclophosphamide, each followed by docetaxel and trastuzumab, as neoadjuvant therapy for HER2-positive breast cancer
2008-000709-12Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Apr 2008
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of doxorubicin, cyclophosphamide, trastuzumab and docetaxel in breast cancer (2 arms), sponsored by Cephalon, Inc. Primary endpoint: pathological complete response. Started Apr 2008; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-000709-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000709-12.